BioCentury
ARTICLE | Clinical News

B244: Phase IIb started

September 26, 2016 7:00 AM UTC

AOBiome began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 4x10 9 colony forming units (CFUs)/mL B244 topical spray administered to the face twice daily for 12 weeks in about 3...